Details of the Drug

General Information of Drug (ID: DMGP8WX)

Drug Name

ANG-3777

Synonyms

Terevalefim; Refanalin; Terevalefim [INN]; ANG-3777; 1070881-42-3; Terevalefim [USAN]; SNV-003; 500128-99-4; GG91UXK2M5; Terevalefim [USAN:INN]; UNII-GG91UXK2M5; 5-((E)-2-Thiophen-2-yl-vinyl)-lh-pyrazole; 5-[(E)-2-thiophen-2-ylethenyl]-1H-pyrazole; (e)-5-(2-(thiophen-2-yl)vinyl)-1h-pyrazole; WHO 11458; 3-[2-(2-thienyl)ethenyl]-1H-Pyrazole; 1H-Pyrazole, 3-((1E)-2-(2-thienyl)ethenyl)-; BB3; TEREVALEFIM [WHO-DD]; BB-3; SCHEMBL1225335; CHEMBL4650326; SCHEMBL10149623; GTPL11997; ANG3777; GLXC-26914; AKOS040755926; MS-22944; HY-137455; 5-[2-(thiophen-2-yl)ethenyl]-1H-pyrazole; CS-0138662; E80357; (E)-3-(2-(thiophen-2-yl)vinyl)-1H-pyrazole; EN300-7830322; 5-[(E)-2-(thiophen-2-yl)ethenyl]-1H-pyrazole; EN300-18541705

Indication

Disease Entry	ICD 11	Status	REF
Delayed graft function	4B24.0	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL is unavailable

2D MOL

Chemical Identifiers

Formula: C9H8N2S
Canonical SMILES: C1=CSC(=C1)C=CC2=CC=NN2
InChI: InChI=1S/C9H8N2S/c1-2-9(12-7-1)4-3-8-5-6-10-11-8/h1-7H,(H,10,11)/b4-3+
InChIKey: FOHWAQGURRYJFK-ONEGZZNKSA-N

Cross-matching ID

PubChem CID: 5714038
TTD ID: D5E2KR

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hepatocyte growth factor (HGF)	TT4V2JM	HGF_HUMAN	Mimetic	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Delayed graft function

ICD Disease Classification

4B24.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Hepatocyte growth factor (HGF)	DTT	HGF	4.90E-01	0.13	2.73
Hepatocyte growth factor (HGF)	DTT	HGF	1.98E-07	1.58	2.92

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT02474667) A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of ANG-3777 (Formerly BB3) to Improve Graft Function and Reduce the Severity of Kidney Dysfunction or Delayed Graft Function Following Kidney Transplantation in Recipients of a Deceased Donor Kidney. U.S.National Institutes of Health.
2	Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury. Kidney Int Rep. 2020 Sep 25;5(12):2325-2332.